Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$86.59 USD
-4.59 (-5.03%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $86.64 +0.05 (0.06%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.59 USD
-4.59 (-5.03%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $86.64 +0.05 (0.06%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Zacks News
Down 19% in 4 Weeks, Here's Why Axsome (AXSM) Looks Ripe for a Turnaround
by Zacks Equity Research
Axsome (AXSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study
by Zacks Equity Research
ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.
Implied Volatility Surging for Axsome (AXSM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
How Much Upside is Left in Axsome (AXSM)? Wall Street Analysts Think 144%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 143.7% in Axsome (AXSM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More
by Kinjel Shah
Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.
Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12
by Zacks Equity Research
Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance
by Zacks Equity Research
Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.
Axsome (AXSM) Up 11.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug
by Zacks Equity Research
FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.
Is the Options Market Predicting a Spike in Axsome (AXSM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Axsome (AXSM) Q2 Earnings Top, AXS-05 Approval Likely Delayed
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports narrower-than-expected Q2 loss. Yet, share price falls steeply after it notified of a potential delay in the approval of AXS-05 for major depressive disorder
Axsome Therapeutics (AXSM) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Axsome Therapeutics (AXSM) has been struggling lately, but the selling pressure may be coming to an end soon.
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
by Zacks Equity Research
The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
Why Is Axsome (AXSM) Up 14.7% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)
by Zacks Equity Research
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases first-quarter 2021 results.
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, which has been developed in partnership with Pfizer.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Editas (EDIT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.